{"id":28632,"date":"2024-02-02T09:30:00","date_gmt":"2024-02-02T09:30:00","guid":{"rendered":"https:\/\/g-medtech.com\/news\/?p=28632"},"modified":"2026-01-12T12:48:40","modified_gmt":"2026-01-12T12:48:40","slug":"arteraai-closes-20-million-in-new-funding","status":"publish","type":"post","link":"https:\/\/g-medtech.com\/news\/jp\/arteraai-closes-20-million-in-new-funding\/","title":{"rendered":"ArteraAI Closes $20 Million in New Funding"},"content":{"rendered":"<p class=\"wp-block-paragraph\"><a href=\"https:\/\/g-medtech.com\/database\/medtech-players\/index\/artera\/\" target=\"_blank\" rel=\"noreferrer noopener\">ArteraAI<\/a> has closed an additional $20 million in new financing, following closely on the heels of its recent achievement of the Centers for Medicare and Medicaid Services (CMS) decision on the payment rate for the ArteraAI Prostate Test.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The funding was led by prominent large investment funds including Prosperity7 Ventures, <a href=\"https:\/\/g-medtech.com\/database\/medtech-players\/index\/edbi\/\" target=\"_blank\" rel=\"noreferrer noopener\">EDBI<\/a>, Walden Catalyst Ventures, Wilson Sonsini Goodrich &amp; Rosati, and Trium Ventures.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Less than a year ago, ArteraAI emerged from stealth mode with an initial funding of $90M. Since then, the company has made significant strides, obtaining a Medicare payment rate, growing distribution and establishing a solid foundation for international expansion through strategic global partnerships to continue its research.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cThe infusion of this additional funding is a crucial catalyst, propelling ArteraAI forward in its mission to personalize cancer therapy through AI-enabled predictive and prognostic tests,\u201d said Andre Esteva, CEO and Co-Founder of ArteraAI. \u201cWe are committed to ushering in the era of precision medicine, and stewarding this investment strategically to aid in our international expansion and commercial growth.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cInvesting in ArteraAI wasn&#8217;t just a financial decision, but a testament to ArteraAI which is globally revolutionizing patient care,\u201d said Abhishek Shukla at Prosperity7 Ventures. \u201cWe are thrilled to be part of the journey as ArteraAI continues its mission to provide patients with access to personalized cancer treatment plans.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cArteraAI\u2019s AI-driven tests represent a transformative approach to designing tailored cancer care regimens. This offers a glimpse into the future where cancer care is truly personalized, aligning with Singapore\u2019s efforts to digitize healthcare and harness AI to enable precision medicine,\u201d said Dr. Jolene Ooi, Senior Principal at EDBI. \u201cWe are excited to be part of their growth story and look forward to supporting its foray into Asia.\u201d<\/p>","protected":false},"excerpt":{"rendered":"<p>The funding will support the international expansion and commercial growth of the company and its first-of-its-kind test<\/p>","protected":false},"author":2,"featured_media":28633,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"colormag_page_layout":"default_layout","footnotes":""},"categories":[7,488,675,10],"tags":[594],"class_list":["post-28632","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-americas","category-breaking-news","category-ivds","category-strategic-development","tag-financing"],"_links":{"self":[{"href":"https:\/\/g-medtech.com\/news\/jp\/wp-json\/wp\/v2\/posts\/28632","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/g-medtech.com\/news\/jp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/g-medtech.com\/news\/jp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/g-medtech.com\/news\/jp\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/g-medtech.com\/news\/jp\/wp-json\/wp\/v2\/comments?post=28632"}],"version-history":[{"count":6,"href":"https:\/\/g-medtech.com\/news\/jp\/wp-json\/wp\/v2\/posts\/28632\/revisions"}],"predecessor-version":[{"id":38155,"href":"https:\/\/g-medtech.com\/news\/jp\/wp-json\/wp\/v2\/posts\/28632\/revisions\/38155"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/g-medtech.com\/news\/jp\/wp-json\/wp\/v2\/media\/28633"}],"wp:attachment":[{"href":"https:\/\/g-medtech.com\/news\/jp\/wp-json\/wp\/v2\/media?parent=28632"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/g-medtech.com\/news\/jp\/wp-json\/wp\/v2\/categories?post=28632"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/g-medtech.com\/news\/jp\/wp-json\/wp\/v2\/tags?post=28632"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}